Nonnucleoside RT Inhibitor (NNRTI) Resistance Mutations: Percent Occurrence in Patients Treated with Dual nucleoside RT inhibitor (NRTI) plus NNRTI First Line Antiretroviral (ARV) Regimens.

Footnote: *No.: Number of patients receiving first-line therapy with the ARV regimen indicated in the first two columns.†The proportion of individuals treated with NVP or EFV. Mutations for which there were statistically significant differences according to the NNRTI received: **p≤0.001.Fewer sequences were included in table 4 than in table 3 as sequences that terminated between positions 219 and 229 were excluded from the numerator and denominator for NNRTI mutation statistics.